<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302233239
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEXTROSE 5% + 0.9% SODIUM CHLORIDE INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXTROSE,SODIUM CHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,0.9
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AL RAZI PHARMA INDUSTRIES FACTORY LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES FACTORY LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2312]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AL RAZI PHARMA INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B05BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        B05CB01
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">5% Dextrose and 0.9% Sodium Chloride Injection is a clear colorless solution of Dextrose Monohydrate and Sodium Chloride in water. The solution is stored in a sealed flexible Polyethylene bottle.<br />5% Dextrose and 0.9% Sodium Chloride Injection is a solution of the following substances in water:<br />&bull; Sugar (Dextrose).<br />&bull; Sodium chloride.<br />Dextrose is one of the body&rsquo;s sources of energy. This solution for infusion provides 170 kilocalories per liter.<br />Sodium and chloride are chemical substances found in the blood.<br />5% Dextrose and 0.9% Sodium Chloride Injection is used:<br />&bull; As a source of carbohydrate (sugar).<br />&bull; To treat a loss of sodium from the blood and the body (sodium depletion).<br />&bull; To treat a loss of body water, for example after being sick or having diarrhea (extracellular dehydration).<br />&bull; To treat you, if the volume of blood in your blood vessels is low (hypovolemia).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do NOT receive 5% Dextrose and 0.9% Sodium Chloride Injection if you are suffering from any of the following conditions:</strong><br />&bull; An allergy to the product or any of the other ingredients.<br />&bull; When there is too much fluid in the spaces around the cells of the body (extracellular hyperhydration).<br />&bull; When there is a larger volume of blood in the blood vessels than there should be (hypervolemia).<br />&bull; More fluid and sodium than normal in the body (fluid and sodium retention).<br />&bull; Severe kidney problems that mean you produce less urine than usual or none at all (oliguria or anuria).<br />&bull; Uncompensated heart failure. This is heart failure that is not adequately treated and causes symptoms such as:<br />o Shortness of breath.<br />o Swelling of the ankles.<br />&bull; Higher levels of sodium in the blood than normal (hypernatremia).<br />&bull; Higher levels of chloride in the blood than normal (hyperchloraemia).<br />&bull; Buildup of fluid under the skin, affecting all parts of the body (general oedema).<br />&bull; Liver disease that causes fluid to build up within the abdomen (ascitic cirrhosis).<br />&bull; Diabetes that is not adequately treated, allowing your blood sugar levels to rise above normal (uncompensated diabetes);<br />&bull; Other states of Dextrose intolerance, for example:<br />o Metabolic stress (when the body&rsquo;s metabolism does not function correctly, e.g. due to severe illness).<br />o Hyperosmolar coma (unconsciousness). This is a type of coma that can occur if you have diabetes and do not receive enough medicine.<br />o A very high amount of sugar in the blood (significant hyperglycemia).<br />o Higher levels of lactate in the blood than normal (hyperlactatemia).</p><p dir="ltr"><strong>Take Special Care with 5% Dextrose and 0.9% Sodium Chloride Injection:</strong><br />Please tell your doctor if you have or have had any of the following medical conditions:<br />&bull; A disorder in which the blood becomes too alkaline (metabolic alkalosis).<br />&bull; Muscle weakness and periodic paralysis due to low thyroid activity (thyrotoxic periodic paralysis).<br />&bull; Rapid loss of water from the body e.g. due to vomiting or diarrhea.<br />&bull; Being on a low potassium diet for a long time.<br />&bull; Taking certain medications, See below, &ldquo;Other medicines and 5% Dextrose and 0.9% Sodium Chloride Injection&rdquo;.<br />&bull; A disorder in which the blood becomes too acidic (metabolic acidosis).<br />Conditions associated with sodium retention, fluid overload and oedema, such as:<br />&bull; Aldosteronism (a disease that causes high levels of a hormone called aldosterone) associated with poor liver function or liver disease that causes fluid to build up within the abdomen (ascetic cirrhosis).<br />&bull; High blood pressure (hypertension).<br />&bull; Heart failure.<br />&bull; Poor kidney function.<br />&bull; High blood pressure during pregnancy (preeclampsia).<br />&bull; Any other condition associated with sodium retention (when the body retains too much sodium), such as treatment with steroids (See also below, &ldquo;Other medicines and 5% Dextrose and 0.9% Sodium Chloride Injection&rdquo;).<br />&bull; Allergy, in particular to corn (5 % Dextrose and 0.9% Sodium Chloride Injection contains sugar derived from corn).</p><p dir="ltr">The infusion may cause:<br />&bull; Changes in the concentrations of the chemicals in the blood (electrolyte disturbances).<br />&bull; Buildup of fluid under the skin, affecting all parts of the body (general oedema), around the ankles (peripheral oedema) or in the lungs (pulmonary oedema).<br />&bull; A higher amount of sugar in the blood than normal (hyperglycemia).<br />When you are given this infusion, your doctor will take blood and urine samples to monitor:<br />&bull; The amount of chemicals such as sodium and chloride in your blood (your plasma electrolytes).<br />&bull; The amount of sugar (Dextrose).<br />As 5% Dextrose and 0.9% Sodium Chloride contains sugar (Dextrose), it can cause a high level of sugar in the blood (hyperglycemia). If this occurs, your doctor may:<br />&bull; Adjust the speed of infusion.<br />&bull; Give you insulin to reduce the blood sugar levels.<br />This is particularly important:<br />&bull; If you are diabetic.<br />&bull; If you have not been eating well or have been drinking too much alcohol for a long time.<br />&bull; If you have recently had a stroke (acute ischaemic stroke). High levels of sugar in the blood can worsen the effects of stroke and affect recovery.&nbsp;</p><p dir="ltr">&bull; If you have had head injury within the past 24 hours.</p><p dir="ltr">Your doctor will take into account if you are receiving parenteral nutrition (nutrition given by infusion into a vein). During long-term treatment with 5 % Dextrose and 0.9% Sodium Chloride Injection, you may need to be given extra nutrition. Your doctor should also monitor the level of potassium in your blood to avoid this becoming lower than normal (hypokalemia).</p><p dir="ltr"><br /><strong>Children</strong><br />Special care should be taken when giving this solution to children, infants, and newborns (especially premature babies and those with low birth weight). Children, infants and newborns may not have a good ability to handle the chemicals in the solution.<br />Newborns &ndash; especially those born premature and with low birth weight - are at increased risk of developing a too low or too high level of sugar in the blood (hypo- or hyperglycemia) and therefore need close monitoring during treatment with intravenous solutions containing Dextrose to ensure adequate control of the sugar levels in order to avoid potential long term adverse effects.<br />Low sugar levels in the newborn can cause prolonged seizures, coma and brain damage. High sugar levels have been associated with bleeding into the brain, late onset bacterial and fungal infection, damage to the eye (retinopathy of prematurity), infections in the intestinal track (necrotizing enterocolitis), lung problems (bronchopulmonary dysplasia), prolonged hospital stay and death.<br />Children are at higher risk for having or developing a too low sodium concentration in their blood (hyponatraemia). Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain (cerebral oedema) and death. Acute hyponatraemic encephalopathy is a serious complication, especially in children. Your doctor knows this and will closely monitor the amount of chemicals such as sodium and chloride in your child&rsquo;s blood (plasma electrolytes).<br /><strong>Using other Medicines, Herbal or Dietary Supplements:</strong><br />Tell your doctor if you are taking or have recently taken any other medicines.<br /><strong>It is particularly important that you inform your doctor if you are taking:</strong><br />&bull; Corticosteroids (anti-inflammatory medicines). These medicines can cause the body to accumulate sodium and water, leading to:<br />o Tissue swelling due to fluid collection under the skin (oedema).<br />o High blood pressure (hypertension).<br />Other medicines that can affect or be affected by this product:<br />&bull; Lithium (used to treat psychiatric illnesses).<br />&bull; Insulin (used to treat diabetes).<br />&bull; Water tablets (diuretics).<br />&bull; Beta blockers (heart tablets).<br />5 % Dextrose and 0.9% Sodium Chloride Injection must not be given through the same needle as a blood transfusion. This can damage the red blood cells or cause them to clump together.<br />5% Dextrose and 0.9% Sodium Chloride Injection with Food and Drink:<br />You should ask your doctor about what you can eat or drink.<br /><strong>Pregnancy and Breast-Feeding:</strong><br />If you are pregnant or breast-feeding, or think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine. 5% Dextrose and 0.9% Sodium Chloride Injection can be used during breastfeeding. If another medicine is to be added to your solution for infusion during pregnancy or <strong>breast-feeding you should:</strong><br />&bull; Consult your doctor.<br />&bull; Read the Package Leaflet of the medicine that is to be added.<br /><strong>Driving and Using Machines:</strong><br />5% Dextrose and 0.9% Sodium Chloride Injection has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">This medicine is administered to you by a doctor or healthcare professional in hospital.<br />Your doctor will decide on how much you need and when it is to be given. This will depend on your age, weight, condition and the reason for treatment. The amount you are given may also be affected by other treatments you are receiving.<br />You should NOT be given 5 % Dextrose and 0.9% Sodium Chloride Injection if there are particles floating in the solution or if the pack is damaged in any way.<br />5 % Dextrose and 0.9% Sodium Chloride Injection will usually be given to you through a plastic tube attached to a needle in a vein. However, your doctor may use another method to give you the medicine.<br />Any unused solution should be thrown away. You should not be given an infusion of 5 % Dextrose and 0.9% Sodium Chloride Injection from a bag that has been partly used.<br /><strong>If you Use more 5% Dextrose and 0.9% Sodium Chloride Injection than you should:</strong><br />If you are given too much 5 % Dextrose and 0.9% Sodium Chloride Injection (over-infusion) or if it is given too fast, this may lead to the following symptoms:<br />&bull; Dry mouth due to lack of water in body tissues (dehydration).<br />&bull; Thirst.<br />&bull; Frequent urination due to increased urine production (osmotic diuresis).<br />&bull; Blurred vision.<br />&bull; Fatigue.<br />&bull; Low levels of sodium in the blood (hyponatraemia). Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, swelling of the brain (cerebral oedema) and death.<br />&bull; High blood levels of sodium (hypernatremia). If they occur, the most serious effect is a reduction in the water content of the brain (dehydration of the brain). This causes drowsiness and confusion and may lead to fits (convulsions), unconsciousness (coma), stopping breathing (respiratory failure) and even death.<br /><strong>Other symptoms include:</strong><br />&bull; Fever.<br />&bull; Rapid heart rate (tachycardia).<br />&bull; High blood pressure (hypertension).<br />&bull; Headache, Restlessness, Irritability and Weakness.<br />&bull; Build-up of fluid in the body causing swelling (oedema).<br />If you develop any of these symptoms you must inform your doctor immediately. Your infusion will be stopped and you will be given treatment depending on the symptoms.<br />If a medicine has been added to your 5 % Dextrose and 0.9% Sodium Chloride Injection before over infusion occurs, that medicine may also cause symptoms. You should read the Package Leaflet of the added medicine for a list of possible symptoms.<br />Stop receiving your 5 % Dextrose and 0.9% Sodium Chloride Injection:<br />Your doctor will decide when to stop giving you this infusion.<br />If you have any further questions on the use of this product, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>The infusion should be stopped immediately if you experience an adverse reaction:</strong><br />If you are given the solution for a long time, you may notice the following:<br />&bull; Hypersensitivity reactions, including a serious allergic reaction called anaphylaxis (potential manifestation in patients with allergy to corn).<br />&bull; Higher levels of sodium in the blood than normal (hypernatremia).<br />&bull; Higher levels of sugar in the blood than normal (hyperglycemia).<br />The side effects can be related to the administration technique. This includes:<br />&bull; Fever (febrile response).<br />&bull; Chills.<br />&bull; Itching (pruritus) or rash.<br />&bull; Local pain or reaction (pain or vesicles at the site of infusion).<br />&bull; Irritation and inflammation of the vein into which the solution is infused (phlebitis). This can cause redness, pain or burning and swelling along the path of the vein into which the solution is infused.<br />If a medicine has been added to the solution for infusion, the added medicine may also cause side effects. These side effects will depend on the medicine that has been added. You should read the Package Leaflet of the added medicine for a list of possible symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />The solution should only be used if it is clear and the container is not damaged.<br />It should be used immediately. For single use only. Any unused solution in the bottle must be discarded.<br />Do not throw away any medicines via wastewater or household waste. The doctor or nurse will dispose of this medicine. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substances are:<br />&bull; Sugar (Dextrose): 50 g per liter.<br />&bull; Sodium chloride: 9 g per liter.<br />The only other ingredient is water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                5% Dextrose and 0.9% Sodium Chloride Injection is a clear colorless solution. The solution for infusion is packaged in a container. It is available in size of 500 mL.
It is Available in:
polyethylene Bottles.
Contents: 500 mL
Supplied in Packs of:
20 x 500 mL.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorization Manufacturer and Holder:</strong><br />AL RAZI PHARMA INDUSTRIES</p><p dir="ltr">2nd Industrial City &ndash; Street No. 67 Cross 110 Building No. 3992</p><p dir="ltr">Dammam, Kingdom of Saudi Arabia.</p><p dir="ltr">.Tel: +966 13 8281919<br />Fax: +966 13 8281313<br />Website: www.alrazi-pharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الدكستروز ٪5 وكلوريد الصوديو م %0.9 ، محلول نقي&nbsp;من كلوريد&nbsp;الصوديوم ومونوهيدرات الدكستروز في الماء. المحلو ل معبأ في وعا ء من بولي ايثيلين<br />المختوم .<br />محلول كلوريد الصوديوم والدكستروز الوريدي يتكون من المواد التالية في الماء :<br />&bull; السكر ( الدكسترو ز ) .<br />&bull; كلوريد الصوديوم .<br />الدكستروز هو احد مصادر الطاقة في الجسم. هذا المحلول يوفر 170 سعرة حرارية لكل لتر.الصوديوم والكلور مواد كيميائية توجد في الدم .<br />محلول كلوريد الصوديوم والدكستروز الوريدي يستخدم :<br />&bull; كمصدر للكربوهيدرات (السكر).<br />&bull; لعلاج فقدان الصوديوم من الدم والجسم (نضوب الصوديوم) .<br />. لعلاج فقدان الماء من الجسم، على سبيل المثال بعد أن تكون مريضا أو وجود الإسهال (الجفاف خارج الخلية) .</p><p>&bull; لعلاجك، إذا كان حجم الدم في الأوعية الدموية منخفض (نقص حجم الدم) .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم محلول الدكستروز و كلوريد الصوديو م الوريدي اذا :<br />&bull; كنت تعاني من حساسية لهذا المنتج أو أي من المكونات الأخرى .<br />&bull; كان هناك تجمع للسوائل حول خلايا الجسم (فرط التميه خارج الخلية) .<br />&bull; كان حجم الدم في الأوعية الدموية أكبر من مما ينبغي (فرط حجم الدم) .<br />&bull; كانت كمية السوائل والصوديوم أكثرمن المعتاد في الجسم (احتباس السوائل والصوديوم) .<br />&bull; كنت تعاني من مشاكل شديدة في الكلى حيث يكون التبول أقل من المعتاد أو لا شيء على الإطلاق(قلة البول أو انقطاع البول) .<br />&bull; كنت تعاني من فشل في القلب بدون تعويض. وهو الذي لم يعالج بشكل نهائي، ويسبب أعراض مثل :<br />-ضيق في التنفس&nbsp;.<br />-تورم الكاحلين .<br />&bull; كانت مستويات الصوديوم في الدم أعلى من المعدل الطبيعي(فرط الصوديوم في الدم).<br />&bull; كانت مستويات الكلوريد في الدم أعلى من المعدل الطبيعي (فرط الكلور في الدم)&nbsp;.<br />&bull; كنت تعاني من تراكم السوائل تحت الجلد، والتي تؤثر على جميع أجزاء الجسم (وذمة عامة)&nbsp;.<br />&bull; كنت تعاني من أمراض الكبد التي تسبب احتباس السوائل داخل البطن( تليف الكبد) .<br />&bull; كنت تعاني من مرض السكري الغير معالج بشكل كاف، مما يتيح لمستويات السكر في الدم بالارتفاع فوق المعدل الطبيعي(السكري غير<br />المعوض) .<br />&bull; كان هناك حساسية مفرطة للدكستروز، على سبيل المثال :<br />-إجهاد العمليات الأيضية (العمليات الأيضية في الجسم لاتتم بشكل صحيح، بسبب مرض شديد مثلا)&nbsp;.<br />-غيبوبة السكر. هذا هو نوع من الغيبوبة يمكن أن يحدث إذا كان لديك مرض السكري ولا تأخذ الدواء بشكل كاف .<br />-ارتفاع مستوى السكر في الدم .</p><p><strong>الإحتياطات والتحذيرا ت :</strong><br />تحدث إلى طبيبك&nbsp;أو الممرضة إذا كنت تعاني او عانيت مؤخرا من :<br />&bull; اضطراب حيث يصبح فيه الدم قلوي جدا (استقلاب قلوي).<br />&bull; ضعف العضلات أوالشلل المتكرر بسبب انخفاض نشاط الغدة الدرقية (التسمم الدرقي)&nbsp;.<br />&bull; فقدان سريع للماء من الجسم بسبب القيء أو الإسهال .<br />&bull; اتباع نظام غذائي منخفض البوتاسيوم لفترة طويلة .<br />&bull; أخذ بعض الأدوية، انظر أدناه، &quot;الأدوية الأخرى ومحلول الدكستروز و كلوريد الصوديوم الوريد ي &quot; .<br />&bull; اضطراب حيث يصبح فيه الدم حامضي جدا (استقلاب حمضي) .<br /><strong>حالات لها علاقة باحتباس الصوديوم والسوائل مثل :</strong><br />&bull; المرض المرتبط مع ضعف وظائف الكبد أو أمراض الكبد بسبب ارتفاع مستويات هرمون الألدوستيرون والذ ي يسبب تجمع السوائل داخل<br />البطن (تليف الكبد).<br />&bull; ارتفاع ضغط الدم .<br />&bull; فشل القلب .<br />&bull; ضعف وظائف الكلى .<br />&bull; ارتفاع ضغط الدم أثناء الحمل(تسمم الحمل) .<br />&bull; أي حالة أخرى مرتبطة باحتباس الصوديوم (عندما يحتفظ الجسم بكمية كبيرة من الصوديوم)، مثل العلاج مع المنشطات )انظر أيضا أدناه،<br />&quot; الأدوية الأخرى ومحلول الدكستروز و كلوريد الصوديوم الوريدي&quot; .<br />&bull; الحساسية .<br /><strong>المحلول الوريدي قد يسبب :</strong><br />&bull; تغييرات في تركيز المواد الكيميائية في الدم (اضطرابات الإلكتروليتات).<br />&bull; تراكم السوائل تحت الجلد، والتي تؤثر على جميع أجزاء الجسم(وذمة عامة)، في جميع أنحاء الكاحلين (وذمة محيطية) أو في الرئتين<br />(الوذمة الرئوية) .<br />&bull; ارتفاع مستوى السكر في الدم أكثر من المعتاد (فرط سكر الدم) .<br /><strong>عندما يتم إعطاء هذا االمحلول، سيقوم الطبيب بأخذ عينات الدم والبول لمراقبة :</strong><br />&bull; مستوى المواد الكيميائية مثل الصوديوم والكلوريد في الدم (الإلكتروليتات) .<br />&bull; مستوى السكر (الدكستروز).<br /><strong>بما أن المحلول يحتوي على دكستروز 5 ٪ و كلوريد الصوديوم 0.9 ٪ ،فإنه يمكن أن يسبب ارتفاع مستوى السكر في الدم ،إذا حدث هذا، طبيبك قد :</strong><br />&bull; يضبط سرعة الضخ .<br />&bull; يصرف الانسولين لتقليل مستويات السكر في الدم، وهذا أمر مهم على وجه الخصوص:</p><p dir="ltr">إذا كنت مصابا بمرض السكري . -<br />إذا لم تأكل جيدا أو تناولت الكثير من الكحول لفترة طويلة . -<br />إذا عانيت مؤخرا من السكتة الدماغية (السكتة الدماغية الحادة). المستويات العالية من السكر في الدم يمكن أن تفاقم آثار السكتة -<br />الدماغية وتؤثر على العلاج .</p><p>إذا كان لديك إصابة في الرأس خلال ال&nbsp; 24 ساعة الماضية .</p><p>طبيبك سوف يأخذ في الاعتبار إذا كنت تتلقى المحاليل الوريدية، خلال فترة العلاج طويلة الأمد مع دكستروز 5 ٪ و كلوريد الصوديوم 0.9 ٪ ، قد تحتاج إلى إعطاء<br />التغذية الإضافية. الطبيب يجب أيضا يراقب مستوى البوتاسيوم في الدم لتجنب أن يصبح أقل من المعدل الطبيعي(نقص البوتاسيوم في الدم) .<br /><strong>الأطفال :</strong><br />يجب توخي الحذر خاصة عند اعطاء هذا المحلول للأطفال ،الرضع، والأطفال حديثي الولادة (الأطفال الخدج خاصة والذين يعانون من انخفاض الوزن عند الولادة).<br />الأطفال ،الرضع والأطفال حديثي الولادة قد لا يكون لهم القدرة الجيدة على التعامل مع المواد الكيميائية التي في المحلول .<br />الأطفال حديثي الولادة - وخاصة الخدج او الذين يعانون من انخفاض الوزن عند الولادة &ndash; هم الأكثر عرضة لخطر ارتفاع او انخفاض حاد في مستوى السكر في<br />الدم )ارتفاع أو انخفاض السكر(، وبالتالي نتحتاج الى المراقبة عن كثب خلال فت رة العلاج بالمحاليل الوريدية التي تحتوي على الدكستروز لضمان السيطرة الكافية<br />لمستويات السكر وذلك لتجنب الآثار السلبية المحتملة على المدى الطويل .<br />المستويات المنخفضة من السكر في الأطفال حديثي الولادة يمكن أن تسبب نوبات لفترات طويلة، غيبوبة، أوتلف في الدماغ. بينما المستويات العالية من السكر تسبب نزيف في المخ ، العدوى المتأخرة من البكتيريا والفطريات ، ضرر في العين )اعتلال الشبكية من الولادة المبكرة(، التهابات في مسار الأمعاء )التهاب الأمعاء(، مشاكل في الرئة )خلل النسيج القصبي الرئوي(، البقاء في المستشفى لفترات طويلة و الموت .<br />الأطفال هم الأكثر عرضة لانخفاض مستوى الصوديوم الحاد في الدم(نقص صوديوم الدم). نقص صوديوم الدم يمكن أن يؤدي إلى الصداع، الغثيان، التشنج، الخمول،<br />الغيبوبة، تورم في الدماغ (وذمة دماغية) والموت. نقص الصوديوم الحاد في الدماغ هو من االمضاعفات الخطيرة&nbsp;وخاصة عند الأطفال. طبيبك يعلم هذا وسوف يراقب عن كثب كمية المواد الكيميائية مثل الصوديوم والكلوريد في الدم (الكتروليتات البلازما) .</p><p><strong>إستخدام أدوية أخرى ، اعشاب أو مكملات غذائية&nbsp;:</strong><br />يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى ، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية .<br />من المهم جدا ابلاغ طبيبك إذا كنت تأخذ :<br />&bull; الكورتيزون (الأدوية المضادة للالتهابات). هذه الأدوية يمكن أن يتسبب تراكم الصوديوم والماء في الجسم ، مما يؤدي إلى&nbsp;:<br />o تورم الأنسجة نتيجة لتجمع السوائل تحت الجلد (وذمة) .<br />o ارتفاع ضغط الدم .<br />الأدوية الأخرى التي يمكن أن تؤثر أو تتأثر بهذا الدواء :<br />&bull; الليثيوم (يستخدم لعلاج الأمراض النفسية) .<br />&bull; الأنسولين(يستخدم لعلاج مرض السكري) .<br />&bull; مدرات البول .<br />&bull; حاصرات بيتا(أقراص القلب) .</p><p>يجب ألا تعطى محلول الدكستروز 5٪ و كلوريد الصوديوم 0.9 ٪ من نفس الإبرة التي تستخدم لنقل الدم ، لأنه يؤدي إلى تلف خلايا الدم الحمراء أو التصاقهم مع بعض .</p><p><strong><u>محلول الدكستروز 5% و كلوريد الصوديوم 0.9 ٪ مع الطعام والشراب :</u></strong><br />يجب عليك أن تسأل طبيبك حول ما يمكنك تناوله من الطعام أو الشراب .</p><p><strong>الحمل والرضاعة الطبيعية :</strong><br />إذا كنت حاملا أ و ترضعين طفلك رضاعة طبيعية ، أو تعتقدين ان تكوني حاملا، أو تخططين لإنجاب طفل، اسألي طبيبك للحصول على المشورة قبل أن تعطي هذا<br />الدوا ء .<br />محلول الدكستروز 5% و كلوريد الصوديوم 0.9 ٪ يمكن استخدامه أثناء الرضاعة الطبيعية .<br />إذاكان هناك دواء آخر سيضاف إلى هذا المحلول أثناء الحمل أو الرضاعة الطبيعية يجب :<br />&bull; استشارة طبيبك .<br />&bull; قراءة النشرة الداخلية للدواء الذي تريد إضافته</p><p><strong>القيادة والآلات المستخدمة</strong><br />محلول الدكستروز 5% و كلوريد الصوديوم 0.9 ٪ ليس له تأثير على قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يعطى هذا الدواء في المستشفى من قبل الطبيب أو الممارسين الصحيين المتخصصين&nbsp;.<br />سوف يقرر الطبيب الكمية والوقت المناسبين للجرعة ،وهذا يعتمد على العمر،الوزن وسبب العلاج. الجرعة المناسبة أيضا تتأثر بالعلاجات الأخرى التي تتلقاها .<br />محلول الدكستروز 5% و كلوريد الصوديوم 0.9 ٪ ينبغي ألا يعطى إذا كانت هناك جسيمات عائمة في المحلول أو كان هناك تلف في العبوة بأي شكل من الأشكا ل .<br />عادة يعطى المحلول من خلال أنبوب بلاستيكي متصل بإبرة في الوريد. ومع ذلك، قد يستخدم طبيبك طريقة أخرى لإعطائك الدواء</p><p>يجب التخلص من كمية المحلول الغير المستخدمة وعدم استخدامها مرة أخرى</p><p><strong>اذا اعطيت المحلول اكثر مما يجب :</strong><br />إذا كانت كمية المحلول اكثر من الجرعة المناسبة أو إذا كان التسريب بسرعة كبيرة، فهذا قد يؤدي إلى الأعراض التالية :<br />&bull; جفاف الفم بسبب نقص المياه في أنسجة الجسم )الجفاف( .<br />&bull; العطش<br />&bull; كثرة التبول نتيجة لزيادة إنتاج البول )إدرار البول التناضحي( .<br />&bull; الرؤية غير الواضحة .<br />&bull; التعب .<br />&bull; ارتفاع مستوى الصوديوم في الدم. في حالة حدوثه، فإن انخف اض مستوى الماء في الدماغ )جفاف الدماغ(أخطر الاعراض حدوثا. حيث<br />يسبب النعاس والارتباك وربما يؤدي إلى نوبات )التشنجات(، فقدان الوعي )غيبوبة(، وقف التنفس و الموت.<br /><strong>الأعراض الأخرى هي :</strong><br />&bull; العطش .<br />&bull; جفاف الفم والعينين .<br />&bull; الحمى .<br />&bull; سرعة دقات القلب )عدم انتظام دقات القلب( .<br />&bull; ارتفاع ضغط الدم .<br />&bull; الصداع ، الأر ق ، التهيج اوالضعف&nbsp;.<br />&bull; تراكم السوائل في الجسم مما يسبب التورم )وذمة( .<br />إذا حدثت أي من تلك الأعراض يجب إبلاغ الطبيب فورا. سيتم إيقاف المحلول فورا، وسيتم إعطاء العلاج اعتمادا على الأعراض .<br />إذا تمت إضافة دواء لمحلول الدكستروز 5% و كلوريد الصوديوم 0.9 ٪ قبل حدوث الجرعة الزائدة، فإن الدواء المضاف قد يكون له علاقة بتلك الأعراض، لذا يجب<br />قراءة النشرة الداخية للدواء المضاف (الأعراض الجانبية المحتملة) .<br /><strong>إيقاف استخدام محلول الدكستروز 5% و كلوريد الصوديوم 0.9 %&nbsp;:</strong><br />طبيبك سوف يقرر متى يتوقف استخدام المحلول .<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل طبيبك أو الممرضة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الادوية ، يمكن لهذا الدواء أن يسبب آثارا جانبية، على الرغم من أن الغالبية لا يحصل لهم .<br />يجب أن يتوقف المحلول فورا إذا واجهت أي رد فعل سلبي .<br />إذا أعطيت المحلول لفترة طويلة، قد تلاحظ ما يلي :<br />&bull; الحساسية، بما في ذلك الحساسية المفرطة الخطيرة (ممكنة في المرضى الذين يعانون من حساسية من الذرة) .<br />&bull; ارتفاع مستوى الصوديوم في الدم (فرط صوديوم الدم) .<br />&bull; ارتفاع مستوى السكر في الدم (فرط سكر الدم) .<br />الآثار الجانبية التي لها علاقة بطرقة الحقن، هذا يتضمن :<br />&bull; الحمى (الاستجابة الحموية) .<br />&bull; القشعريرة .<br />&bull; الحكة أو الطفح الجلدي .<br />&bull; ألم موضعي أو رد فعل (ألم أو انتفاخ في موقع الحقن) .<br />&bull; تهيج والتهاب الوريد الذي تم الحقن فيه. وقد يسبب احمرار ، ألم ، حرقان اوتورم في مكان الحقن .<br />إذا تمت إضافة دواء إلى المحلول، الدواء المضاف قد يسبب آثار جانبية. يجب قراءة النشرة الداخلية للدواء المضاف (قائمة الأعراض المحتملة) .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيداً عن متناول الاطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الذي ذكر على الملصق .تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر .<br />لا تقم بتخزينه فوق 30 درجة مئوية&nbsp;.<br />المحلول يجب أن يستعمل فقط إذا كان شفاف اً وغير معطوب الحاوية. وينبغي أن تستخدم فورا بعد إزالة الغطاء. المحلول للاستخدام مرة واحدة فقط.</p><p>يجب عدم رمي أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. سيقوم الطبيب أو الممرضة التخلص من هذا الدواء. سوف تساعد هذه التدابير لحماية&nbsp;البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة هي :<br />&bull; السكر (دكستروز): 50 جم لكل لتر .<br />&bull; كلوريد الصوديوم: 9 جم لكل لتر .<br />العنصر الآخر هو الماء المعد للحقن</p><p><br />&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو محلول الدكستروز 5 % وكلوريد الصوديوم 0.9 % الوريدي وماهي محتويات العبوة ؟</strong><br />هو محلول شفاف ، عديم اللو ن من كلوريد الصوديو م والدكستروز في الماء . معبأ في عبوا ت بولي ايثيلين مغلقة، متوفر بحجم 500 مل .<br />متوفر في: عبوات البولي ايثيلين&nbsp;.<br />المحتوى: 500 مل<br />حجم الكرتون: 20 &times; 500 مل</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع وحامل ترخيص التسويق :</strong><br />مصنع شركة الرازي للصناعات الدوائية</p><p>المملكة العربية السعودية &ndash; الدمام &ndash; المدينة الصناعية الثانية .<br />ص.ب 3992 &ndash; الدمام 34332 - 6963 .<br />ت : 1919 828 13 966 +<br />فاكس: 1313 828 13 966 +<br />الموقع الإلكتروني:&nbsp;<strong>www.alrazi-pharma.com</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5% Dextrose and 0.9% Sodium Chloride Injection USP 500mL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dextrose Monohydrate:50 g/L. Sodium Chloride: 9 g/L. Each ml contains 50mg Dextrose Monohydrate and 9 mg Sodium Chloride.
Mmol/l: Na+ : 154 Cl- :154
Meq/l: Na+ : 154 Cl- :154

 Nutritional value: approximately 711 kJ/l (or 170 kcal/l).
 For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
Clear solution, free from visible particles.
Osmolarity 560 mOsmol/l (approx.).
 pH: 3.2 – 6.5.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride 0.9 % w/v and Dextrose 5% w/v solution is indicated for the Treatment of sodium depletion, extracellular dehydration or hypovolaemia in cases where supply of water and carbohydrates is required due to restriction of the intake of fluids and electrolytes by normal routes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The choice of the specific sodium chloride and Dextrose concentration, dosage, volume, rate and duration of administration depends on the age, weight, clinical condition of the patient and concomitant therapy. It should be determined by a physician. For patients with electrolyte and Dextrose abnormalities and for paediatric patients, consult a physician experienced in intravenous fluid therapy.</p><p dir="ltr">Rapid correction of hyponatraemia and hypernatraemia is potentially dangerous (risk of serious neurologic complications).</p><p dir="ltr"><strong>Adults, Older Patients And Adolescents (Age 12 Years And Over):</strong><br />The recommended dosage is: 500 ml to 3 L/24h.</p><p dir="ltr">Administration rate:<br />The infusion rate is usually 40 ml/kg/24h and should not exceed the patient&rsquo;s Dextrose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum acute administration rate is 5 mg/kg/min.<br /><strong>Paediatric Population:</strong><br />The dosage varies with weight: &bull;<br />0-10 kg body weight: 100 ml / kg / 24 h.<br />10-20 kg body weight: 1000 ml + (50 ml/ kg over 10 kg) / 24h.<br />&gt; 20 kg body weight: 1500 ml + (20 ml/ kg over 20 kg) / 24h.<br /><strong>Administration rate:</strong><br />The administration rate varies with weight:<br />0-10 kg body weight: 6-8 ml/kg/h.<br />10-20 kg body weight: 4-6 ml/kg/h<br />&gt; 20 kg body weight: 2-4 ml/kg/h.<br />The infusion rate should not exceed the patient&rsquo;s Dextrose oxidation capacities in order to avoid hyperglycaemia. Therefore the maximum acute administration rate is 10-18 mg/kg/min depending on the total body mass.<br />For all patients, a gradual increase of flow rate should be considered when starting administration of Dextrose containing products.<br /><strong>Method of Administration:</strong><br />The administration is performed by intravenous infusion.<br />Precautions to be taken before manipulating or administering the product:<br />Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless the solution is clear and the seal is intact. Administer immediately following the insertion of infusion set. Do not remove unit from overwrap until ready for use. The inner bag maintains the sterility of the product.<br />The solution should be administered with sterile equipment using an aseptic technique.<br />The equipment should be primed with the solution in order to prevent air entering the system.<br />Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in&nbsp;&nbsp;flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers<br />Additives may be introduced before or during infusion through the resealable medication port. When additive is used, verify tonicity prior to parenteral administration. Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, any hyperosmolar solution is recommended to be administered through a large central vein, for rapid dilution of the hyperosmotic solution.<br />For further information on the product with additives, please see sections 6.2, 6.3 and 6.6.<br /><strong>Monitoring:</strong><br />Fluid balance and the concentrations of Dextrose and electrolytes (especially sodium) in plasma must be monitored during administration. Electrolyte supplementation may be indicated according to the clinical needs of the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The solution is contraindicated in patients presenting with:
Known hypersensitivity to the product
Extracellular hyperhydration or hypervolaemia
Fluid and sodium retention
Severe renal insufficiency (with oliguria/anuria)
Uncompensated cardiac failure
Hypernatraemia or hyperchloraemia
General oedema and ascetic cirrhosis
Clinically significant hyperglycaemia. The solution is also contraindicated in case of uncompensated diabetes, other known Dextrose intolerances (such as metabolic stress situations), hyperosmolar coma or hyperlactataemia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Hypokalaemia: The infusion of Sodium chloride 0.9% w/v and Dextrose 5% w/v solution may result in hypokalaemia. Close clinical monitoring may be warranted in patients with or at risk for hypokalaemia, for example:</p><p dir="ltr"> Persons with metabolic alkalosis<br /> Persons with thyrotoxic periodic paralysis. Administration of intravenous Dextrose has been associated in aggravating hypokalaemia<br /> Persons with increased gastrointestinal losses (e.g., diarrhea, vomiting)<br /> Prolonged low potassium diet<br /> Persons with primary hyperaldosteronism<br /> Patients treated with medications that increase the risk of hypokalaemia (e.g. diuretics, beta-2 agonists or insulin)<br /><strong>Sodium Retention, Fluid Overload and Oedema:</strong><br />Sodium chloride 0.9% w/v and Dextrose 5% w/v solution should be used with particular caution in<br /> Patients with metabolic acidosis<br /> Patients at risk of<br />o Hypernatraemia<br />o Hyperchloraemia<br />o Hypervolaemia<br /> Patients with conditions that may cause sodium retention, fluid overload and oedema (central and peripheral), such as,.<br />o o Primary hyperaldosteronism,<br />o Secondary hyperaldosteronism associated with, for example,<br /> hypertension,<br /> congestive heart failure,<br /> liver disease (including cirrhosis),<br /> renal disease (including renal artery stenosis, nephrosclerosis)<br />o Pre-eclampsia.<br />Patients taking medications that may increase the risk of sodium and fluid retention, such as corticosteroids</p><p dir="ltr"><strong>Hyperosmolality, Serum Electrolytes And Water Imbalance:</strong><br />Depending on the volume, rate of infusion, the patient&rsquo;s underlying clinical condition and capability to metabolize Dextrose, administration of Sodium chloride 0.9% w/v and Dextrose 5% w/v solution can cause:<br /> Hyperosmolality, osmotic diuresis and dehydration<br /> Electrolyte disturbances such as<br />o hyponatraemia (see &ldquo;Sodium imbalance&rdquo; below)<br />o hypokalaemia (see above)<br />o hypophosphataemia,<br />o hypomagnesaemia,<br /> Acid-base imbalance<br /> Overhydration/hypervolaemia and, for example, congested s tates, including central (e.g. pulmonary congestion) and peripheral oedema.<br /> An increase in serum Dextrose concentration is associated with an increase in serum osmolality. Osmotic diuresis associated with hyperglycaemia can result in or contribute to the development of dehydration and in electrolyte losses.<br />Sodium Imbalance:<br />Sodium chloride 0.9% w/v and Dextrose 5% w/v solution should be used with particular caution in patients with; or at risk for hyponatraemia, for example:<br /> children<br /> elderly patients<br /> women<br /> postoperatively<br /> persons with psychogenic polydipsia<br />Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema, and death. Acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.<br />Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.</p><p dir="ltr"><strong>Hyperglycaemia:</strong><br />Rapid administration of Dextrose solutions may produce substantial hyperglycaemia and hyperosmolar syndrome. In order to avoid hyperglycaemia the infusion rate should not exceed the patient&rsquo;s ability to utilize Dextrose. To reduce the risk of hyperglycaemia-associated complications, the infusion rate must be adjusted and/or insulin administered if blood Dextrose levels exceed levels considered acceptable for the individual patient.<br />Intravenous Dextrose should be administered with caution in patients with, for example:<br />Impaired glucose tolerance (such as in diabetes mellitus, renal impairment, or in the presence of sepsis, trauma, or shock),<br />Severe malnutrition (risk of precipitating a refeeding syndrome, see below),<br />Thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic acidosis due to impaired oxidative metabolism of pyruvate),<br />Water and electrolyte disturbances that could be aggravated by increased glucose and/or free water load.<br />Other groups of patients in whom 5% Dextrose and 0.9% Sodium Chloride Injection solution should be used with caution include:<br /> Patients with ischemic stroke. Hyperglycaemia has been implicated in increasing cerebral ischemic brain damage and impairing recovery after acute ischemic strokes.<br /> Patients with severe traumatic brain injury (in particular during the first 24 hours following the trauma). Early hyperglycaemia has been associated with poor outcomes in patients with severe traumatic brain injury.<br /> Newborns (See Paediatric glycaemia-related issues).<br />Prolonged intravenous administration of glucose and associated hyperglycaemia may result in decreased rates of glucose-stimulated insulin secretion.<br /><strong>Hypersensitivity Reactions:</strong><br />Hypersensitivity/infusion reactions, including anaphylaxis, have been reported (see section 4.8).<br />Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.<br />Solutions containing glucose should be used with caution in patients with known allergy to corn or corn products.</p><p dir="ltr"><strong>Refeeding Syndrome:</strong><br />Refeeding severely undernourished patients may result in the refeeding syndrome that is characterized by the shift of potassium, phosphorus, and magnesium intracellularly as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. Careful monitoring and slowly increasing nutrient intake while avoiding overfeeding can prevent these complications.</p><p dir="ltr"><strong>Severe renal Impairment:</strong><br />5% Dextrose and 0.9% Sodium Chloride Injection solution should be administered with particular caution to patients at risk of (severe) renal impairment. In such patients, administration may result in sodium retention and/or fluid overload.<br />Paediatric Use:<br />The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy, and should be determined by a physician experienced in paediatric intravenous fluid therapy.<br />Pediatric glycaemia-related issues:<br />Newborns, especially those born premature and with low birth weight, are at increased risk of developing hypo- or hyperglycaemia. Close monitoring during treatment with intravenous glucose solutions is needed to ensure adequate glycaemic control, in order to avoid potential long term adverse effects.<br />Hypoglycaemia in the newborn can cause, e.g., prolonged seizures, coma, and cerebral injury<br />Hyperglycaemia has been associated with cerebral injury, including intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, increased oxygen requirements, prolonged length of hospital stay, and death..<br />Paediatric Hyponatraemia-Related Issues:<br />Children (including neonates and older children) are at increased risk of developing hyponatraemia as well as for developing hyponatraemic encephalopathy.<br /> Hyponatraemia can lead to headache, nausea, seizures, lethargy, coma, cerebral oedema and death; therefore, acute symptomatic hyponatraemic encephalopathy is considered a medical emergency.<br /> Plasma electrolyte concentrations should be closely monitored in the paediatric population</p><p dir="ltr">Rapid correction of hyponatraemia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in paediatric intravenous fluid therapy.</p><p dir="ltr"><strong>Blood:</strong><br />5% Dextrose and 0.9% Sodium Chloride Injection solution should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or haemolysis.<br /><strong>Geriatric Use:</strong><br />When selecting the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic and other diseases or concomitant drug therapy.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Both the glycaemic and effects on water and electrolyte balance should be taken into account when administering 5% Dextrose and 0.9% Sodium Chloride Injection solution to patients treated with other substances that affect glycaemic control, or fluid and/or electrolyte balance.<br />Caution is advised in patients treated with,<br /> Lithium. Renal sodium and lithium clearance may be increased during administration and can result in decreased lithium levels.<br /> Corticosteroids, which are associated with the retention of sodium and water (with oedema and hypertension).<br /> Diuretics, beta-2 agonists or insulin, whom increase the risk of hypokalemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Fertility:</strong><br />There is no information on the effects of 5% Dextrose and 0.9% Sodium Chloride Injection solution on fertility.<br /><strong>Pregnancy:</strong><br />Intrapartum maternal intravenous glucose infusion may result in foetal hyperglycaemia and metabolic acidosis as well as rebound neonatal hypoglycaemia due to foetal insulin production.<br /><strong>Lactation:</strong><br />5% Dextrose and 0.9% Sodium Chloride Injection solution can be used during breastfeeding.</p><p dir="ltr">The potential risks and benefits for each specific patient should be carefully considered before administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is no information on the effects of 5% Dextrose and 0.9% Sodium Chloride Injection solution on the ability to operate an automobile or other heavy machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The following adverse reactions have been reported in post-marketing experience, listed by MedDRA System Organ Class (SOC), then where feasible, by Preferred Term in order of severity.<br />Frequencies cannot be estimated from the available data, as all listed adverse reactions are based on spontaneous reporting.</p><p dir="ltr"><img alt="" width="833" height="413" src="data:image/jpeg;base64,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" /></p><p dir="ltr">Note: Potential manifestation in patients with allergy to corn, see section 4.4<br />Other adverse reactions reported with isotonic saline and glucose infusions include:<br />Hyponatraemia, which may be symptomatic<br />Hyperchloraemic acidosis<br />Adverse reactions may be associated to the medicinal product(s) added to the solution; the nature of the additive will determine the likelihood of any other adverse reactions.</p><p dir="ltr"><strong>Reporting of suspected adverse reactions:</strong><br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to SFDA.<br />Note: To report any side effects please contact;<br />National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free Phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Excess administration of 5% Dextrose and 0.9% Sodium Chloride Injection solution can cause:<br />Hyperglycaemia, adverse effects on water and electrolyte balance and corresponding complications. For example, severe hyperglycaemia and severe dilutional hyponatraemia and their complications, can be fatal.<br />Hyponatraemia (which can lead to CNS manifestations, including seizures, coma, cerebral edema and death).<br />Hypernatraemia especially in patients with severe renal impairment.<br />Fluid overload (which can lead to central and/or peripheral edema).<br />See also sections 4.4 and 4.8.<br />A clinically significant overdose of 5% Dextrose and 0.9% Sodium Chloride Injection solution may, therefore, constitute a medical emergency.<br />When assessing an overdose, any additives in the solution must also be considered..<br />Interventions include discontinuation of 5% Dextrose and 0.9% Sodium Chloride Injection solution administration, dose reduction, administration of insulin and other measures as indicated for the specific clinical constellation</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group &ldquo;Electrolytes with Carbohydrates&rdquo;, ATC code: &ldquo;B05BB02.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The pharmacokinetic properties of this solution are those of its components (glucose, sodium and chloride).<br />After injection of radiosodium (24Na), the half-life is 11 to 13 days for 99% of the injected Na and one year for the remaining 1%. The distribution varies according to tissues: it is fast in muscles, liver, kidney, cartilage and skin; it is slow in erythrocytes and neurons; it is very slow in the bone. Sodium is predominantly excreted by the kidneys, but (as described earlier).<br />There is extensive renal reabsorption. Small amounts of sodium are lost in the faeces and sweat. The two main metabolic pathways of glucose are gluconeogenesis (energy storage) and glycogenolysis (energy release). Glucose metabolism is regulated by insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical safety data of this solution for infusion in animals are not relevant since its constituents are physiological components of animal and human plasma.&nbsp;<br />Toxic effects are not to be expected under the condition of clinical application. The safety of potential additives should be considered separately.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Incompatibility of the medicinal product to be added with the solution in container must be assessed before addition. In the absence of compatibility studies, this solution must not be mixed with other medicinal products.<br />The Instructions for Use of the medicinal product to be added must be consulted. Before adding a drug, verify it is soluble and stable in water at the pH of 5% Dextrose and 0.9% Sodium Chloride Injection (see section 3).<br />As guidance, the following medications are incompatible with the 5% Dextrose and 0.9% Sodium Chloride Injection (non-exhaustive listing):<br />Ampicillin sodium<br />Mitomycin<br />Amphotericin B<br />Those additives known to be incompatible should not be used.<br />Because of the presence of glucose, 5% Dextrose and 0.9% Sodium Chloride Injection should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or haemolysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The container is made of Low Density-Polyethylene (LDPE) The primary packaging material Low Density-Polyethylene (LDPE) is used for several years in the pharmaceutical industry for the primary packaging of comparable drug products. The material is known for its compatibility with the ingredients of the drug product.<br />The container material, LD (Low Density)-polyethylene meets the requirements of the European Pharmacopoeia (Ph. Eur. 3.2.2).<br />The material shows a density of 0.9%26-0.9%30 g/cm3.The container can be sterilised at temperatures between 106-112 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">For single use only. Do not use unless the solution is clear and the container undamaged. Discard any unused solution.<br />Any unused product or waste material should be disposed of in accordance with local requirements.<br />Addition of medicinal products:<br />Confirm additive compatibility before use.<br />Clean the injection site using antiseptic solution.<br />Carefully introduce the sterile needle into the sterile chamber in the injection site, attach the needle to the container with the medicinal product, introduce the needle through the second membrane into the bag and inject the medicine. Carefully withdraw the needle.<br />Mix thoroughly with the solution. Use immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AL RAZI PHARMA INDUSTRIES, 
Building No.3992 Street No 67.Cross 110,2nd Industrial City, 
Dammam Kingdom of Saudi Arabia 
– Tel: +966138281919, Fax: +966138251414, 
Website: www.alrazi-pharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>